Dr. Pavel Tyan is a surgeon, oncologist, and researcher, and now, has been appointed at the therapeutic lead for oncology at Advanced Clinical. Tyan has worked across both the pharmaceutical and CRO industries, with a focus on immuno-oncology programs.
“My ultimate goal is to make Advanced Clinical visible for oncology-focused pharma and biotech in Europe and worldwide, to demonstrate that Advanced Clinical could be the right and attractive partner for clinical trials execution in oncology,” he told us.
To meet this goal, Tyan said supporting activities will include developing a ‘foundation’ of high performing investigational sites, which will enable the company’s clients “to get the quick access to scientific expert’s advices, desired patient’s population as well as the good quality clinical trial data.”
Initial discussions with European research centers are underway, Tyan said, adding that he has received positive feedback from the sites expressing a ‘high interest’ to collaborate.
“The plan is to embrace not only such traditional for oncology clinical research in Europe countries like Central and Western European countries but to extend the Advanced Clinical outreach farther east to Russia and its neighboring countries which possess tremendous potential for oncology clinical trials,” he explained.
“In addition, I believe that my vision on how to ensure the medical monitoring excellence specifically in oncology clinical trials, developed through the years of experience of working for numerous pharmaceutical companies, biotech and CROs will find the fertile ground in this very dynamic, collaborative and open-minded atmosphere at Advanced Clinical.”